News Lilly's triple G overpowers Ozempic in diabetes trial Eli Lilly has added another arrow to the quiver of new diabetes and obesity drug retatrutide, outperforming Novo's Ozempic in a head-to-head trial.
News Judge backs Lilly in Novo lawsuit over weight-loss drug ads A US judge has blocked Novo's request for an injunction on Eli Lilly's advertising for weight-loss and diabetes drugs Mounjaro and Zepbound.
News UEGW delegates hear of strides forward in IBD treatment Trials of Lilly's Omvoh, Gilead's emvistegrast, Takeda's Entyvio, AbbVie's ABBV-466, and Sanofi/Teva's duvakitug are highlights of UEGW.
News CHMP backs Lilly's oral GLP-1 Foundayo for EU approval Eli Lilly's oral GLP-1 Foundayo has been recommended for weight reduction and type 2 diabetes in the EU, plus other CHMP decisions.
News Lilly's Zepbound enhances Taltz efficacy in psoriasis study A study has shown that the efficacy of Lilly's psoriasis therapy Taltz is improved when it is given in combination with weight-loss drug Zepbound.
News UK watchdog takes first action on oral weight drug adverts Online pharmacies operating in the UK breached Advertising Standards Authority rules by promoting oral weight drugs to the public.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.